FibroBiologics (FBLG) Cash from Financing Activities (2023 - 2026)

FibroBiologics has reported Cash from Financing Activities for 4 years, with the latest figure at $5.3 million in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at $5.3 million, up 21.69% year-over-year; the trailing twelve-month figure through Jun 2026 was $9.5 million (down 47.92% YoY), and the FY2025 annual result was $7.6 million, down 55.26% from the prior year.
• Cash from Financing Activities rose to $5.3 million in Q2 2026, from $952000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $14.6 million in Q1 2023 and troughed at -$1.7 million in Q2 2023.
• A 4-year average of $4.0 million and a median of $3.3 million in 2024 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2024, when Cash from Financing Activities plunged 77.5%; it then surged 2643.6% in 2025.
• A 4-year view of Cash from Financing Activities shows it stood at $940000.0 in 2023, then soared by 892.55% to $9.3 million in 2024, then tumbled by 65.81% to $3.2 million in 2025, then surged by 66.9% to $5.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $5.3 million in Q2 2026, $952000.0 in Q1 2026, and $3.2 million in Q4 2025.